Shepherd Financial Partners’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-3,766
| Closed | -$240K | – | 245 |
|
|
2025
Q1 | $240K | Hold |
3,766
| – | – | 0.03% | 214 |
|
|
2024
Q4 | $458K | Hold |
3,766
| – | – | 0.05% | 146 |
|
|
2024
Q3 | $470K | Hold |
3,766
| – | – | 0.06% | 150 |
|
|
2024
Q2 | $595K | Hold |
3,766
| – | – | 0.08% | 134 |
|
|
2024
Q1 | $488K | Hold |
3,766
| – | – | 0.06% | 150 |
|
|
2023
Q4 | $363K | Hold |
3,766
| – | – | 0.05% | 167 |
|
|
2023
Q3 | $457K | Hold |
3,766
| – | – | 0.07% | 138 |
|
|
2023
Q2 | $431K | Hold |
3,766
| – | – | 0.07% | 137 |
|
|
2023
Q1 | $519K | Hold |
3,766
| – | – | 0.09% | 127 |
|
|
2022
Q4 | $488K | Hold |
3,766
| – | – | 0.09% | 124 |
|
|
2022
Q3 | $416K | Sell |
3,766
-23
| -0.6% | -$2.32K | 0.08% | 124 |
|
|
2022
Q2 | $284K | Hold |
3,789
| – | – | 0.06% | 138 |
|
|
2022
Q1 | $296K | Sell |
3,789
-5,083
| -57% | -$389K | 0.05% | 141 |
|
|
2021
Q4 | $799K | Sell |
8,872
-12
| -0.1% | -$1.03K | 0.14% | 93 |
|
|
2021
Q3 | $821K | Sell |
8,884
-1,375
| -13% | -$106K | 0.16% | 92 |
|
|
2021
Q2 | $798K | Sell |
10,259
-159
| -2% | -$12.1K | 0.15% | 94 |
|
|
2021
Q1 | $776K | Sell |
10,418
-7,774
| -43% | -$717K | 0.17% | 98 |
|
|
2020
Q4 | $3.1M | Buy |
18,192
+704
| +4% | +$104K | 0.71% | 26 |
|
|
2020
Q3 | $2.46M | Buy |
17,488
+7,965
| +84% | +$1.21M | 0.58% | 27 |
|
|
2020
Q2 | $1.53M | Hold |
9,523
| – | – | 0.41% | 43 |
|
|
2020
Q1 | $931K | Hold |
9,523
| – | – | 0.32% | 51 |
|
|
2019
Q4 | $1.23M | Hold |
9,523
| – | – | 0.29% | 59 |
|
|
2019
Q3 | $717K | Sell |
9,523
-85
| -0.9% | -$10K | 0.18% | 74 |
|
|
2019
Q2 | $1.46M | Hold |
9,608
| – | – | 0.27% | 51 |
|
|
2019
Q1 | $1.15M | Sell |
9,608
-50
| -0.5% | -$6.43K | 0.22% | 56 |
|
|
2018
Q4 | $1.05M | Sell |
9,658
-15
| -0.2% | -$1.88K | 0.23% | 54 |
|
|
2018
Q3 | $1.28M | Hold |
9,673
| – | – | 0.29% | 53 |
|
|
2018
Q2 | $1.3M | Hold |
9,673
| – | – | 0.29% | 53 |
|
|
2018
Q1 | $716K | Hold |
9,673
| – | – | 0.18% | 62 |
|
|
2017
Q4 | $539K | Buy |
9,673
+1,340
| +16% | +$71K | 0.13% | 76 |
|
|
2017
Q3 | $427K | Hold |
8,333
| – | – | 0.1% | 86 |
|
|
2017
Q2 | $284K | Hold |
8,333
| – | – | 0.07% | 95 |
|
|
2017
Q1 | $243K | Hold |
8,333
| – | – | 0.06% | 101 |
|
|
2016
Q4 | $233K | Buy |
+8,333
| New | +$335K | 0.07% | 98 |
|
Other funds holding SRPT
EAM
Shepherd Financial Partners's SRPT Position: Q2 2025 in Review
Shepherd Financial Partners sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 3,766 shares — an estimated $240K sold.
Shepherd Financial Partners first reported a position in SRPT in Q4 2016 and held it in 34 quarters. The position peaked at $3.1M in Q4 2020. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.
- Shepherd Financial Partners reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
- Shepherd Financial Partners sold 3,766 Sarepta Therapeutics shares in Q2 2025, an estimated $240K.
- Shepherd Financial Partners first reported a position in Sarepta Therapeutics in Q4 2016 and held it in 34 quarters.
- Shepherd Financial Partners's Sarepta Therapeutics position peaked at $3.1M in Q4 2020.
- 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.
Based on Shepherd Financial Partners's 13F filing for Q2 2025, filed 13 Aug 2025.